Biography

I lead investor relations, corporate affairs and operations at Foghorn Therapeutics, where we’re developing first-in-class precision oncology medicines by targeting genetically defined cancer dependencies in chromatin biology.

I’ve spent my career in biotech and life sciences, from early development through commercialization, across both rare and high-prevalence diseases. Before joining Foghorn, I spent more than a decade at Biogen, most recently as Executive Director and Head of Corporate Affairs for the global Alzheimer’s business, and earlier leading external communications and patient advocacy during periods of intense scrutiny and change.

Those experiences shaped how I lead. I focus on clarity, preparation and disciplined execution. I care about getting the story right early, setting realistic expectations and building trust with stakeholders over time.

At Foghorn, I partner closely with the CEO and the executive team on investor engagement, financing strategy and corporate positioning as we advance our biology platform and pipeline.

Outside of work, I serve on the boards of BioTech Social and UsAgainstAlzheimer’s, reflecting a long-standing commitment to patients and to strengthening the broader biotech ecosystem. I am also on the board of Epoch Biotech, a early stage company developing a disease modifying therapy in Alzheimer's disease.

I believe strong biotech companies are built through rigorous thinking, steady leadership, and trust earned over time. At the heart of that work are good people and strong relationships, teams built on integrity, respect, and a shared mission to improve patients lives. That is how I approach my work and how I strive to lead.